… ProQR annonce des premiers résultats positifs pour l'essai de … CAMBRIDGE, Massachussets, 11 oct. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq :PRQR), une entreprise dédiée … héréditaires dans son ensemble », a déclaré Stephen R. Russell, M.D., professeur Schrage d'ophtalmologie et des …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … to present new data from the InSight study in H2 2021. ProQR’s Presentation Presentation title: Safety and efficacy … Congenital Amaurosis type 10 (LCA10) Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR traite le premier patient dans l’essai STELLAR de Phase … CAMBRIDGE, Massachusetts, 11 mars 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société consacrée à … STELLAR examinera si le QR-421a (traitement par ARN de ProQR) peut ralentir la progression de la maladie, voire …
… ProQR Reaches Agreement with the FDA on Design of Phase 2/3 … & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development of ProQR. “Our regulatory discussions have been very …
… ProQR Announces Positive Findings From an Interim Analysis in … pandemic expected to impact timelines for the pipeline ProQR anticipates its cash runway will fund operations into … Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety profile and …